New Nasal Epinephrine Powder Outperforms ARS Pharma's Neffy in Phase 2 Speed Data
SPRY sits 27% above its 52-week low of $6.66.
Summary
Nasus Pharma announced positive Phase 2 data for its investigational intranasal epinephrine powder, NS002, demonstrating significantly faster absorption to therapeutic levels compared to EpiPen. Crucially, the article positions NS002 as clinically superior to "first-generation needle-free products" like ARS Pharmaceuticals' (SPRY) recently approved liquid nasal spray, Neffy, citing the powder formulation's more consistent and rapid absorption, even under allergic challenge conditions. This represents a material competitive threat to SPRY, whose recent 10-K highlighted increased commercialization efforts for Neffy. The emergence of a potentially superior competitor could significantly impact SPRY's market share and future revenue projections for its flagship product. Traders should monitor Nasus Pharma's planned pivotal study in Q4 2026 and anticipated NDA submission by mid-2027, as this could reshape the needle-free epinephrine market.
At the time of this announcement, SPRY was trading at $8.44 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $833.1M. The 52-week trading range was $6.66 to $18.90. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: FinanceWire.